Vitamin D – time for action
Article written by Christine Clark Is there case for mass vitamin D supplementation to mitigate the effects of covid-19?
Article written by Christine Clark Is there case for mass vitamin D supplementation to mitigate the effects of covid-19?
Article written by Christine Clark A meta-analysis of 11 randomised clinical trials of ivermectin to treat covid-19 infection shows a resoundingly positive effect.
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai.
Article written by Christine Clark and Colin Brown We are hearing almost hourly warnings of how the NHS will soon be overwhelmed with Covid-19 cases. Yet we have… read more.
When a virus enters the body, it is picked up by certain cells of the immune system. They transport the virus to the lymph nodes where they present… read more.
Article written by Gary Finnegan There are seven ‘forms of disease’ in people with mild COVID-19, according to scientists at the Medical University of Vienna.
Sex, age, and severity of disease may be useful in identifying COVID-19 survivors who are likely to have high levels of antibodies that can protect against the disease,… read more.
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry… read more.
A comprehensive international study, led by Monash University researchers, has definitively found that pregnancy can delay the onset of multiple sclerosis (MS) by more than 3 years. MS… read more.
Inovio has announced positive interim clinical data of INO 4800 vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase I clinical trial cohorts. In addition, INO… read more.
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.